• Explore /
  • Poster
  • / A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).

A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).

Abstract Poster

Authors

null

Sara A. Hurvitz

David Geffen School of Medicine; University of California, Los Angeles; Jonsson Comprehensive Cancer Center, Santa Monica, CA

Sara A. Hurvitz , Fabrice Andre , Massimo Cristofanilli , Giuseppe Curigliano , Antonio Giordano , Hyo S. Han , Miguel Martin , Barbara Pistilli , Hope S. Rugo , Robert Wesolowski , Samuel Suzuki , Sarah Mutka , Igor Gorbatchevsky , Sibylle Loibl

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

NCT05501886

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS1118)

DOI

10.1200/JCO.2023.41.16_suppl.TPS1118

Abstract #

TPS1118

Poster Bd #

335b

Abstract Disclosures

Similar Posters

First Author: Erika P. Hamilton

First Author: Marzia Del Re

First Author: Fabrice Andre

First Author: Timothy A. Yap